JP2017501201A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501201A5
JP2017501201A5 JP2016544368A JP2016544368A JP2017501201A5 JP 2017501201 A5 JP2017501201 A5 JP 2017501201A5 JP 2016544368 A JP2016544368 A JP 2016544368A JP 2016544368 A JP2016544368 A JP 2016544368A JP 2017501201 A5 JP2017501201 A5 JP 2017501201A5
Authority
JP
Japan
Prior art keywords
pharmaceutical
parts
pharmaceutical composition
composition according
diluents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501201A (ja
JP6588915B2 (ja
Filing date
Publication date
Priority claimed from GBGB1400034.3A external-priority patent/GB201400034D0/en
Application filed filed Critical
Publication of JP2017501201A publication Critical patent/JP2017501201A/ja
Publication of JP2017501201A5 publication Critical patent/JP2017501201A5/ja
Application granted granted Critical
Publication of JP6588915B2 publication Critical patent/JP6588915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2016544368A 2014-01-02 2015-01-02 Ａｚｄ９２９１を含む医薬組成物 Active JP6588915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1400034.3 2014-01-02
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291
PCT/GB2015/050001 WO2015101791A1 (en) 2014-01-02 2015-01-02 Pharmaceutical compositions comprising azd9291

Publications (3)

Publication Number Publication Date
JP2017501201A JP2017501201A (ja) 2017-01-12
JP2017501201A5 true JP2017501201A5 (https=) 2018-02-08
JP6588915B2 JP6588915B2 (ja) 2019-10-09

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544368A Active JP6588915B2 (ja) 2014-01-02 2015-01-02 Ａｚｄ９２９１を含む医薬組成物

Country Status (37)

Country Link
US (6) US10183020B2 (https=)
EP (1) EP3089741B1 (https=)
JP (1) JP6588915B2 (https=)
KR (1) KR102336378B1 (https=)
CN (2) CN114712362A (https=)
AR (1) AR098989A1 (https=)
AU (1) AU2015204218B2 (https=)
CA (1) CA2933403C (https=)
CL (1) CL2016001609A1 (https=)
CR (1) CR20160310A (https=)
CY (1) CY1124848T1 (https=)
DK (1) DK3089741T3 (https=)
DO (1) DOP2016000156A (https=)
EA (1) EA034243B9 (https=)
ES (1) ES2873226T3 (https=)
GB (1) GB201400034D0 (https=)
GT (1) GT201600142A (https=)
HR (1) HRP20210749T1 (https=)
HU (1) HUE054344T2 (https=)
IL (1) IL246186B (https=)
LT (1) LT3089741T (https=)
MX (1) MX367358B (https=)
MY (1) MY183536A (https=)
NI (1) NI201600098A (https=)
NZ (1) NZ721298A (https=)
PE (1) PE20161170A1 (https=)
PH (1) PH12016501310B1 (https=)
PL (1) PL3089741T3 (https=)
PT (1) PT3089741T (https=)
RS (1) RS61927B1 (https=)
SG (1) SG11201605339QA (https=)
SI (1) SI3089741T1 (https=)
SM (1) SMT202100330T1 (https=)
TW (1) TWI702953B (https=)
UY (1) UY35933A (https=)
WO (1) WO2015101791A1 (https=)
ZA (1) ZA201605300B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (https=) 2014-01-24 2018-02-24
AU2017269335B2 (en) 2016-05-26 2021-07-01 Recurium Ip Holdings, Llc EGFR inhibitor compounds
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
KR20260009945A (ko) 2018-02-12 2026-01-20 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙
KR20250002710A (ko) * 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
CN109496150A (zh) * 2018-03-23 2019-03-19 无锡双良生物科技有限公司 一种药物组合物及其制备方法和用途
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR20210144844A (ko) 2019-03-29 2021-11-30 아스트라제네카 아베 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023510426A (ja) 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202304457A (zh) * 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
PE20250268A1 (es) 2022-04-28 2025-01-29 Astrazeneca Ab Compuestos heteroaromaticos biciclicos condensados y uso en el tratamiento del cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
EP4543920A1 (en) 2022-06-27 2025-04-30 Astrazeneca AB Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
TWI901422B (zh) * 2023-10-31 2025-10-11 大陸商浙江同源康醫藥股份有限公司 一種嘧啶類衍生物的藥物組合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2001076565A1 (fr) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions et preparations se desintegrant dans la cavite buccale
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
KR20100090726A (ko) 2002-02-26 2010-08-16 아스트라제네카 아베 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물
CA2582299A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
JP5133071B2 (ja) * 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
CN103702990B (zh) * 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
EP2802314B1 (en) * 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Similar Documents

Publication Publication Date Title
JP2017501201A5 (https=)
JP6588915B2 (ja) Ａｚｄ９２９１を含む医薬組成物
RU2720204C1 (ru) Сублингвальная фармацевтическая композиция эдаравона и (+)-2-борнеола
BRPI0908340A2 (pt) composição farmacêutica para fármacos pouco solúveis
EP2073791B1 (en) Capecitabine pediatric tablets
JPWO2014157137A1 (ja) シロドシンの苦味をマスキングした経口投与製剤
AU2015326392B2 (en) Pharmaceutical compositions comprising alpelisib
JP2012512142A (ja) カペシタビン速崩壊性錠剤
Venkateswarlu et al. Formulation and in vitro evaluation of orlistat orodispersible tablets for enhancement of dissolution rate
ES2674811T3 (es) Composiciones estables de fesoterodina
JP7366108B2 (ja) ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物
AU2007284644B2 (en) Compositions and methods for increasing blood platelet levels in humans
US20170128482A1 (en) Modified release pharmaceutical compositions of sofosbuvir and ribavirin
CN114788817A (zh) 苯海拉明药物组合物
Medarametla et al. Development of Ondansetron Tablets with Advanced Disintegrant Technology for Rapid Release and Improved Pharmacokinetics
JP2020169152A (ja) ロキソプロフェン又はその塩とボタンピとを含有する経口医薬組成物
EP2959888A1 (en) A novel pharmaceutical composition of sofosbuvir and ribavirin
JP2007284394A (ja) 被覆固形製剤
Garg et al. FORMULATION AND EVALUATION OF ORO DISPERSIBLE TABLETS OF GLIBENCLAMIDE
Helen Sonia et al. FORMULATION DEVELOPMENT AND EVALUATION OF TASTE MASKED CEFUROXIME AXETIL DISPERSIBLE TABLETS BY INCLUSION COMPLEXATION WITH β-CYCLODEXTRIN METHOD
TR201516738A2 (tr) Oral terapöti̇k formülasyonlar
WO2013137441A1 (ja) 経口医薬組成物
HK1170673B (en) Compositions and methods for increasing blood platelet levels in humans